Literature DB >> 23749645

Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma.

Kyle Muir1, Antonious Hazim, Ying He, Marion Peyressatre, Do-Young Kim, Xiaoling Song, Laura Beretta.   

Abstract

Nonalcoholic steatohepatitis (NASH) is a common preneoplastic condition of hepatocellular carcinoma (HCC). Mice with hepatocytic deletion of Pten develop NASH and HCC later in life. This model is highly valuable for studies aimed at identifying the molecular mechanism by which metabolic disorders contribute to tumor development. We applied proteomic and lipidomic profiling approaches to Pten-null NASH liver and tumors. Circulating fatty acid composition was also characterized in these mice. The relevance to human NASH and HCC was further validated. This integrative proteomic and lipidomic study from mouse to human and from liver to blood identified the following disease signatures: (i) an HCC signature: upregulated hepatic scd1/scd2, fads2, and acsl5:acsl1 ratio, elevated vaccenic and erucic acids, and reduced margaric and linoleic acids in both liver and plasma; (ii) a NASH signature that correlates with tumor burden: upregulated hepatic elovl6, elevated oleic, adrenic, and osbond acids, and reduced cervonic acid in liver and plasma; and (iii) a NASH signature: reduced hepatic and circulating lignoceric and eicosapentaenoic acids. Altogether, these results show the role of lipid-modifying enzymes converting saturated fatty acids (SFA) to monounsaturated fatty acids (MUFA) in HCC and the importance of an increased ratio of long chain n6-polyunsaturated fatty acids over n3-polyunsaturated fatty acids in NASH and HCC risk. They also highlight the relevance of the Pten-null model for studies related to NASH and HCC and show that circulating lipid metabolome provides a direct read of lipid changes in the liver. Most importantly, novel candidate targets for HCC diagnosis, therapy, risk assessment, and prevention were identified. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23749645      PMCID: PMC3855016          DOI: 10.1158/0008-5472.CAN-12-3797

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  QUANTITATIVE DETERMINATION OF PLASMA FREE FATTY ACIDS AND TRIGLYCERIDES BY THIN-LAYER CHROMATOGRAPHY.

Authors:  G SCHLIERF; P WOOD
Journal:  J Lipid Res       Date:  1965-04       Impact factor: 5.922

2.  In vivo tissue response and degradation behavior of PLLA and stereocomplexed PLA nanofibers.

Authors:  Daisuke Ishii; Tang Hui Ying; Atsushi Mahara; Sunao Murakami; Tetsuji Yamaoka; Won-ki Lee; Tadahisa Iwata
Journal:  Biomacromolecules       Date:  2009-02-09       Impact factor: 6.988

3.  Role of fatty acid elongases in determination of de novo synthesized monounsaturated fatty acid species.

Authors:  Christopher D Green; Cansel G Ozguden-Akkoc; Yun Wang; Donald B Jump; L Karl Olson
Journal:  J Lipid Res       Date:  2010-03-12       Impact factor: 5.922

4.  Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.

Authors:  Diego F Calvisi; Chunmei Wang; Coral Ho; Sara Ladu; Susie A Lee; Sandra Mattu; Giulia Destefanis; Salvatore Delogu; Antje Zimmermann; Johan Ericsson; Stefania Brozzetti; Tommaso Staniscia; Xin Chen; Frank Dombrowski; Matthias Evert
Journal:  Gastroenterology       Date:  2010-12-11       Impact factor: 22.682

5.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas.

Authors:  Yasuo Horie; Akira Suzuki; Ei Kataoka; Takehiko Sasaki; Koichi Hamada; Junko Sasaki; Katsunori Mizuno; Go Hasegawa; Hiroyuki Kishimoto; Masahiro Iizuka; Makoto Naito; Katsuhiko Enomoto; Sumio Watanabe; Tak Wah Mak; Toru Nakano
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

6.  PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism.

Authors:  Manlio Vinciguerra; Christelle Veyrat-Durebex; Moulay Ahmed Moukil; Laura Rubbia-Brandt; Françoise Rohner-Jeanrenaud; Michelangelo Foti
Journal:  Gastroenterology       Date:  2007-10-10       Impact factor: 22.682

7.  A lipidomic analysis of nonalcoholic fatty liver disease.

Authors:  Puneet Puri; Rebecca A Baillie; Michelle M Wiest; Faridoddin Mirshahi; Jayanta Choudhury; Onpan Cheung; Carol Sargeant; Melissa J Contos; Arun J Sanyal
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

8.  Comprehensive and quantitative proteome profiling of the mouse liver and plasma.

Authors:  Keane K Y Lai; Deepak Kolippakkam; Laura Beretta
Journal:  Hepatology       Date:  2008-03       Impact factor: 17.425

9.  Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models.

Authors:  Keane K Y Lai; Sufen Shang; Neha Lohia; Garrett C Booth; Derek J Masse; Nelson Fausto; Jean S Campbell; Laura Beretta
Journal:  PLoS Genet       Date:  2011-06-23       Impact factor: 5.917

Review 10.  De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy.

Authors:  T Mashima; H Seimiya; T Tsuruo
Journal:  Br J Cancer       Date:  2009-04-07       Impact factor: 7.640

View more
  70 in total

Review 1.  The Hepatic Lipidome: A Gateway to Understanding the Pathogenes is of Alcohol-Induced Fatty Liver.

Authors:  Robin D Clugston; Madeleine A Gao; William S Blaner
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

Review 2.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

3.  Stearoyl-CoA Desaturase Promotes Liver Fibrosis and Tumor Development in Mice via a Wnt Positive-Signaling Loop by Stabilization of Low-Density Lipoprotein-Receptor-Related Proteins 5 and 6.

Authors:  Keane K Y Lai; Soo-Mi Kweon; Feng Chi; Edward Hwang; Yasuaki Kabe; Reiichi Higashiyama; Lan Qin; Rui Yan; Raymond P Wu; Keith Lai; Naoaki Fujii; Samuel French; Jun Xu; Jian-Ying Wang; Ramachandran Murali; Lopa Mishra; Ju-Seog Lee; James M Ntambi; Hidekazu Tsukamoto
Journal:  Gastroenterology       Date:  2017-01-29       Impact factor: 22.682

4.  The suppression of hepatic glucose production improves metabolism and insulin sensitivity in subcutaneous adipose tissue in mice.

Authors:  Sylvie Casteras; Aya Abdul-Wahed; Maud Soty; Fanny Vulin; Hervé Guillou; Mélanie Campana; Hervé Le Stunff; Luciano Pirola; Fabienne Rajas; Gilles Mithieux; Amandine Gautier-Stein
Journal:  Diabetologia       Date:  2016-09-09       Impact factor: 10.122

Review 5.  Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Authors:  Chiao-Fang Teng; Han-Chieh Wu; Woei-Cherng Shyu; Long-Bin Jeng; Ih-Jen Su
Journal:  Cell Transplant       Date:  2017-02-14       Impact factor: 4.064

6.  Rapid chromatographic method to decipher distinct alterations in lipid classes in NAFLD/NASH.

Authors:  Stephan Laggai; Yvette Simon; Theo Ranssweiler; Alexandra K Kiemer; Sonja M Kessler
Journal:  World J Hepatol       Date:  2013-10-27

7.  The IGF2 mRNA binding protein p62/IGF2BP2-2 induces fatty acid elongation as a critical feature of steatosis.

Authors:  Stephan Laggai; Sonja M Kessler; Stefan Boettcher; Valérie Lebrun; Katja Gemperlein; Eva Lederer; Isabelle A Leclercq; Rolf Mueller; Rolf W Hartmann; Johannes Haybaeck; Alexandra K Kiemer
Journal:  J Lipid Res       Date:  2014-04-22       Impact factor: 5.922

Review 8.  Molecular Mechanisms Linking Nonalcoholic Steatohepatitis to Cancer.

Authors:  Kara Wegermann; Jeongeun Hyun; Anna Mae Diehl
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-02-01

9.  Systematic integration of molecular profiles identifies miR-22 as a regulator of lipid and folate metabolism in breast cancer cells.

Authors:  C Koufaris; G N Valbuena; Y Pomyen; G D Tredwell; E Nevedomskaya; C-He Lau; T Yang; A Benito; J K Ellis; H C Keun
Journal:  Oncogene       Date:  2015-10-19       Impact factor: 9.867

10.  Elovl6 is a poor prognostic predictor in breast cancer.

Authors:  Yin-Hsun Feng; Wei-Yu Chen; Yu-Hsuan Kuo; Chao-Ling Tung; Chao-Jung Tsao; Ai-Li Shiau; Chao-Liang Wu
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.